Topic
Pertuzumab
About: Pertuzumab is a research topic. Over the lifetime, 1453 publications have been published within this topic receiving 73219 citations. The topic is also known as: 2C4 Antibody & MOAB 2C4.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: There remain many unanswered questions with the use of neoadjuvant chemotherapy in breast cancer, and further randomized clinical trials are needed to permit the clinicians to develop ‘personalized’ treatment approaches, thus giving women the best chance of survival.
Abstract: Purpose of review Although neoadjuvant therapy (NAT) has become a popular approach in the systemic management of breast cancer, several important clinical questions remain unanswered. In this article, we review the literature pertaining to these questions and discuss the management strategies based on our findings. Recent findings Currently, the optimal duration of NAT is unclear. At this time, there is no compelling data to support the extension of traditional neoadjuvant chemotherapy regimens. In patients with triple-negative breast cancer, pathologic complete response may be prognostic and the appropriate use of neoadjuvant chemotherapy is crucial to achieve improved survival. In human epidermal growth factor receptor 2 (HER2)-positive disease, it is reasonable to consider dual blockade with trastuzumab and pertuzumab in combination with a taxane in the neoadjuvant setting. Finally, there is currently no evidence to support the use of further adjuvant chemotherapy in those patients with residual disease after NAT. Summary There remain many unanswered questions with the use of neoadjuvant chemotherapy in breast cancer, and further randomized clinical trials are needed. The results of these trials will permit the clinicians to develop 'personalized' treatment approaches, thus giving women the best chance of survival.
5 citations
••
TL;DR: The incidence of diarrhea was greater with the combination of a taxane and HER2-targeted treatment and decreased once chemotherapy was stopped, and a marked decrease was observed on chemotherapy cessation.
5 citations
••
TL;DR: Preliminary evidence suggests that the use of ACEi, ARB, and beta blockers during treatment with anthracyclines and trastuzumab may prevent subsequent cardiomyopathy and subsequent cardiovascular disease in women with breast cancer.
Abstract: To review cardiotoxicity of and strategies to prevent cardiotoxicity from anthracyclines and anti-HER2 agents used to treat breast cancer. Although not common, cardiotoxicity from anthracyclines and anti-HER2 therapies is a major consideration in the use of these agents, especially in the adjuvant setting. Modifications in anthracycline agent, dosing, or schedule or use of Dexrazoxane have been shown to ameliorate the mostly irreversible cardiotoxicity from anthracyclines. Dose delays have been the primary means of addressing the possibly reversible cardiotoxicity from the anti-HER2 agent, trastuzumab, whereas the other anti-HER2 therapies, pertuzumab, lapatinib, and neratinib, are relatively nontoxic to the myocardium. Data from recent randomized clinical trials suggest that the use of angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), and beta blockers may prevent subclinical cardiotoxicity, as measured by decline in the left ventricular ejection fraction, associated with these agents. Longer-term follow-up will be needed to confirm their role in prevention of symptomatic cardiomyopathy and subsequent cardiovascular disease in women with breast cancer. Preliminary evidence suggests that the use of ACEi, ARB, and beta blockers during treatment with anthracyclines and trastuzumab may prevent subsequent cardiomyopathy. Larger trials with meaningful clinical endpoints are needed.
5 citations
••
TL;DR: In this paper, the authors evaluated the preclinical activity of DHES0815A against primary uterine serous carcinoma (USC) cell lines and xenografts using immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) analysis.
5 citations
••
TL;DR: The NEOSPHERE study, a randomized phase II trial that showed that adding pertuzumab to trastuzumAB and docetaxel nearly doubled the rate of pCR (39.3% vs. 21.5%).
Abstract: NEOSPHERE study, a randomized phase II trial that showed that adding pertuzumab to trastuzumab and docetaxel nearly doubled the rate of pCR (39.3% vs. 21.5%). Additional data from the TRYPHAENA study, as well as longer-term safety data from the phase III CLEOPATRA study of pertuzumab in metastatic breast cancer, were also submitted in support of the approval. (TRYPHAENA is a phase II study of neoadjuvant pertuzumab in earlystage breast cancer designed primarily to assess cardiac safety, but pCR was a secondary endpoint.)
5 citations